Fundsmith LLP Buys 730,300 Shares of Zoetis Inc. $ZTS

Key Points

• Fundsmith LLP raised its stake in Zoetis by 25.3%, buying 730,300 shares in the quarter to hold 3,615,131 shares worth about $529 million (≈0.82% of Zoetis), making ZTS its 16th-largest holding at 2.7% of the fund.
• Zoetis beat the latest quarter with $1.48 EPS on $2.39B revenue, issued FY2026 guidance of $7.00–$7.10 EPS, and trades with a market cap of ~$48.8 billion and a P/E of ~19.2.
• The company declared a quarterly dividend of $0.53 (annualized $2.12, ~1.8% yield), while analyst consensus is a Hold with an average price target of $152.91 (6 Buys, 8 Holds).

Fundsmith LLP raised its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 25.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,615,131 shares of the company's stock after acquiring an additional 730,300 shares during the quarter. Zoetis makes up 2.7% of Fundsmith LLP's holdings, making the stock its 16th biggest position. Fundsmith LLP owned approximately 0.82% of Zoetis worth $528,966,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of ZTS. Brighton Jones LLC raised its holdings in shares of Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock worth $754,000 after purchasing an additional 2,978 shares during the period. Empowered Funds LLC grew its holdings in Zoetis by 6.2% during the first quarter. Empowered Funds LLC now owns 11,293 shares of the company's stock valued at $1,859,000 after purchasing an additional 657 shares during the period. Intech Investment Management LLC grew its holdings in Zoetis by 17.2% during the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company's stock valued at $1,374,000 after purchasing an additional 1,224 shares during the period. Sivia Capital Partners LLC increased its position in Zoetis by 73.8% in the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company's stock worth $522,000 after buying an additional 1,422 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in Zoetis in the second quarter worth $814,000. 92.80% of the stock is owned by institutional investors.

Zoetis Price Performance

Zoetis stock opened at $115.62 on Friday. The firm has a market capitalization of $48.81 billion, a P/E ratio of 19.21, a PEG ratio of 1.76 and a beta of 0.95. Zoetis Inc. has a one year low of $114.47 and a one year high of $172.23. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The business has a fifty day moving average price of $125.34 and a 200-day moving average price of $131.91.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm's revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. Zoetis's dividend payout ratio is currently 35.22%.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. The Goldman Sachs Group raised Zoetis to a "buy" rating in a research report on Monday, December 15th. Morgan Stanley set a $160.00 price objective on Zoetis in a research note on Thursday, December 18th. Weiss Ratings raised shares of Zoetis from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday. UBS Group set a $136.00 target price on shares of Zoetis in a research report on Thursday, January 29th. Finally, Piper Sandler reiterated a "neutral" rating and issued a $135.00 target price (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Six analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $152.91.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.